Morgan Lewis Advises Merck KGaA, Darmstadt, Germany on Sale of Contract Development and Manufacturing Organization to Lonza
November 03, 2026NEW YORK and FRANKFURT, November 3, 2026: Morgan Lewis is advising Merck KGaA, Darmstadt, Germany, a global science and technology company, on its definitive agreement to divest its contract development and manufacturing organization (CDMO) business within its life science business sector to Lonza for a mid-triple-digit million-euro amount. The transaction is expected to close in mid-2027, subject to customary regulatory approvals and other closing conditions.
Merck KGaA, Darmstadt, Germany operates across life science, healthcare, and electronics. With more than 62,000 employees worldwide, the company advances drug development and manufacturing, develops treatments for challenging diseases, and enables next-generation electronic devices. In 2025, Merck generated €21.1 billion in sales across 65 countries.
Morgan Lewis partners Russell Franklin and Meghan Kelly are advising Merck KGaA, Darmstadt, Germany, with a large global team supporting them in connection with the transaction.